Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 2,271 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ovary Disease Clear all

Conditions: Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions: [18F]FPyQCP; Drug
Lead sponsor: Blue Earth Diagnostics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions: Continuous Positive Airway Pressure Device (CPAP), Delayed Continuous Positive Airway Pressure Device (CPAP); Device · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: carboplatin, paclitaxel, cytoreductive surgery; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Ovarian Cancer
Interventions: carboplatin, cisplatin, paclitaxel, topotecan hydrochloride; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 10
States / cities: Fresh Meadows, New York • New York, New York • The Bronx, New York + 2 more

Conditions: Ovarian Neoplasms
Interventions: AZD2281, Liposomal Doxorubicin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Boca Raton, Florida + 3 more

Conditions: Ovarian Insufficiency
Interventions: Group reading and discussion; Other
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Neoplasms, Ovarian Cancer
Interventions: Sacituzumab tirumotecan, Bevacizumab, Rescue Medications; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 27
States / cities: Birmingham, Alabama • Walnut Creek, California • Miami Beach, Florida + 23 more

Conditions: Ovarian Neoplasm, Cancer Genetics, Breast Cancer
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer
Interventions: carboplatin, squalamine lactate; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Constipation, Bowel Obstruction, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cancer
Interventions: aminocamptothecin colloidal dispersion; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: SC-004, ABBV-181; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 12
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Duarte, California + 9 more

Conditions: Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors
Interventions: CDX-585; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Celebration, Florida • New York, New York + 1 more

Conditions: Ovarian Cancer
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ovarian Hyperstimulation Syndrome
Interventions: hCG; Drug
Lead sponsor: UConn Health; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Primary Ovarian Insufficiency
Interventions: Transdermal Estrogen; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 11 Years to 18 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Upifitimab rilsodotin, Placebo; Drug · Other
Lead sponsor: Mersana Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 28
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 23 more

Conditions: Breast Cancer, Ovarian Cancer, Cervical Cancer, Testicular Cancer, Colon Rectal Cancer, Melanoma (Skin Cancer), Endometrial Cancer, Sarcoma, Thyroid Cancer
Interventions: Adapted patient navigation program targeting adolescent and young adult cancer survivors; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 21 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions: galinpepimut-S, pembrolizumab, Montanide, GM-CSF; Biological · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Santa Rosa, California • Whittier, California • Miami, Florida + 9 more

Conditions: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Metastatic Prostate Cancer
Interventions: Standard Genetic Counseling, Educational Video; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Boston, Massachusetts • Brighton, Massachusetts • Milford, Massachusetts + 3 more

Conditions: Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer
Interventions: IMGN151; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 32
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 27 more

Conditions: HER2-expressing Cancers
Interventions: ZW49; Drug
Lead sponsor: Zymeworks BC Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more

Conditions: Breast Cancer, Lung Cancer, Ovarian Cancer
Interventions: HER-2/neu peptide vaccine, sargramostim; Biological
Lead sponsor: University of Washington; Other
Eligibility: Up to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Gynecologic Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer, Lynch Syndrome, Hereditary Breast and Ovarian Cancer Syndrome, Colon Cancer, Endometrial Cancer, Uterus Cancer
Interventions: Free genetic testing and counseling group, IGNITE-TX Group, IGNITE-TX and free genetic testing and counseling group; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Restoring Metabolic and Reproductive Health With Sleep in PCOS Study, CPAP Trial

Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

Deep Reading as a Contemplative Practice for Women With Primary Ovarian Insufficiency

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans

Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer

Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity

SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers

A Study of CDX-585 in Patients With Advanced Malignancies

Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study

Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS

Primary Ovarian Insufficiency: Phenotype and Optimal Treatment

Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

Navigation Intervention for Adolescent and Young Adult Cancer Survivors

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention